A successful collaboration between academia, biotech and pharma led to discovery of erdafitinib, a selective FGFR inhibitor recently approved by the FDA-Reference-Cited by-同舟云学术

A successful collaboration between academia, biotech and pharma led to discovery of erdafitinib, a selective FGFR inhibitor recently approved by the FDA

Published:2019 Issue:9 Volume:10 Page:1509-1511
ISSN:2040-2503
Container-title:MedChemComm
language:en
Short-container-title:Med. Chem. Commun.

Author:

Murray Christopher W.¹²³,Newell David R.⁴⁵⁶³,Angibaud Patrick⁷⁸

Affiliation:

1. Astex Pharmaceuticals

2. Cambridge

3. UK

4. Northern Institute of Cancer Research

5. Newcastle University

6. Newcastle

7. Janssen Cilag

8. France

Abstract

The winners of the Malcolm Campbell Memorial Prize for 2019 discuss the discovery of erdafitinib.

Funder

Cancer Research UK

Publisher

Royal Society of Chemistry (RSC)

Subject

Pharmaceutical Science,Biochemistry,Drug Discovery,Molecular Medicine,Pharmacology,Organic Chemistry

Link

http://pubs.rsc.org/en/content/articlepdf/2019/MD/C9MD90044F

Reference5 articles.

1. Johnson & Johnson press releases (accessed August 16, 2019), ( https://www.jnj.com/media-center/press-releases/janssen-announces-us-fda-breakthrough-therapy-designation-for-erdafitinib-in-the-treatment-of-metastatic-urothelial-cancer ), ( https://www.jnj.com/balversa-erdafitinib-receives-u-s-fda-approval-for-the-treatment-of-patients-with-locally-advanced-or-metastatic-urothelial-carcinoma-with-certain-fgfr-genetic-alterations )

2. Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma

3. Potent, Selective Inhibitors of Fibroblast Growth Factor Receptor Define Fibroblast Growth Factor Dependence in Preclinical Cancer Models

4. Discovery and Pharmacological Characterization of JNJ-42756493 (Erdafitinib), a Functionally Selective Small-Molecule FGFR Family Inhibitor

5. Phase I Dose-Escalation Study of JNJ-42756493, an Oral Pan–Fibroblast Growth Factor Receptor Inhibitor, in Patients With Advanced Solid Tumors

Cited by 60 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Design, synthesis and biological evaluation of 5-amino-1H-pyrazole-4-carboxamide derivatives as pan-FGFR covalent inhibitors;European Journal of Medicinal Chemistry;2024-09

2. A Fragment‐Based Competitive ¹⁹F LB‐NMR Platform For Hotspot‐Directed Ligand Profiling;Angewandte Chemie International Edition;2024-08-12

3. A Fragment‐Based Competitive ¹⁹F LB‐NMR Platform For Hotspot‐Directed Ligand Profiling;Angewandte Chemie;2024-08-12

4. An Update on the Nitrogen Heterocycle Compositions and Properties of U.S. FDA-Approved Pharmaceuticals (2013–2023);Journal of Medicinal Chemistry;2024-07-12

5. Using DNA-encoded libraries of fragments for hit discovery of challenging therapeutic targets;Expert Opinion on Drug Discovery;2024-05-16